Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Holdings Lifted by AQR Capital Management LLC

AQR Capital Management LLC boosted its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 517.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 113,020 shares of the company's stock after acquiring an additional 94,703 shares during the quarter. AQR Capital Management LLC owned about 0.13% of Day One Biopharmaceuticals worth $1,557,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DAWN. Goldman Sachs Group Inc. boosted its stake in shares of Day One Biopharmaceuticals by 28.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company's stock valued at $30,935,000 after buying an additional 472,654 shares during the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of Day One Biopharmaceuticals by 34.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 625,749 shares of the company's stock valued at $9,136,000 after buying an additional 159,341 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Day One Biopharmaceuticals by 19.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company's stock valued at $33,575,000 after buying an additional 336,281 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Day One Biopharmaceuticals by 77.7% during the 4th quarter. Wellington Management Group LLP now owns 208,969 shares of the company's stock valued at $3,051,000 after buying an additional 91,393 shares during the last quarter. Finally, ProShare Advisors LLC boosted its stake in shares of Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company's stock valued at $287,000 after buying an additional 1,447 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company's stock.

Analyst Ratings Changes

DAWN has been the subject of several research analyst reports. Wedbush reiterated an "outperform" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. Bank of America raised Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and upped their price target for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. JPMorgan Chase & Co. dropped their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. Finally, Needham & Company LLC upped their price target on Day One Biopharmaceuticals from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $35.71.

Day One Biopharmaceuticals Stock Up 2.6 %

NASDAQ DAWN traded up $0.35 during trading hours on Friday, hitting $13.88. The company had a trading volume of 1,332,012 shares, compared to its average volume of 923,967. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $9.67 and a fifty-two week high of $18.07. The business has a fifty day simple moving average of $13.88 and a 200-day simple moving average of $14.43. The firm has a market cap of $1.22 billion, a P/E ratio of -7.12 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.70. The company had revenue of $8.19 million during the quarter, compared to analyst estimates of $0.90 million. Equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total value of $320,200.00. Following the sale, the insider now directly owns 1,121,081 shares of the company's stock, valued at $17,948,506.81. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Samuel C. Blackman sold 20,000 shares of the firm's stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total transaction of $320,200.00. Following the transaction, the insider now directly owns 1,121,081 shares of the company's stock, valued at approximately $17,948,506.81. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeremy Bender sold 10,681 shares of the firm's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $149,534.00. Following the transaction, the chief executive officer now directly owns 98,932 shares in the company, valued at $1,385,048. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,748 shares of company stock valued at $1,009,272 over the last three months. Company insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.